Researchers develop light-activated protein-degradation cages
New RuPHOTAC technology uses red light to control when disease-fighting molecules attack proteins, potentially reducing harmful side effects.
What to know
- Researchers have developed RuPHOTACs, light-activated molecular cages that control when protein-degrading drugs become active in the body.
- The technology addresses a major limitation of existing PROTAC drugs: their inability to target specific tissues, which causes systemic side effects.
- By using low-energy red light to activate the cages only in illuminated tissue, RuPHOTACs could enable safer, more localized cancer and disease treatments.
Edith C. (Phoebe) Glazer Professor of chemistry, North Carolina State University
How it unfolded 1 development · click the chart to see its coverage articlesposts
-
1
Mechanism addresses side-effect problem in protein-degradation therapies
The RuPHOTAC technology solves a critical limitation of conventional PROTACs: their inability to target specific tissues. Most disease-associated proteins also perform important functions in healthy cells, so systemic protein degradation causes unwanted side effects. RuPHOTACs enable selective activation only in illuminated tissue.
“The problem is there are very few targets—like aberrant proteins—that are only found in cancer. Most of the time, the proteins are important for our healthy tissues too. So we need a 'cage'; that is, a way to control when and where these PROTACs are activated.”
— Edith C. (Phoebe) Glazer -
S
RuPHOTACs are light-activated molecular cages that keep protein-degrading drug molecules inactive until they are exposed to low-energy red light. # MolecularChemistry # Photochemistry # Pharmacology # CellularBiology # sflorg https://www. sflorg.com/2026/10/chm10292601 .html
-
-
background
Researchers announce RuPHOTAC light-activated protein cages — Researchers have created a molecular cage called RuPHOTACs (ruthenium-based PHOToActivated Chimeras) that keeps protein-degrading drug molecules inactive until exposed to low-energy red light. The technology uses a ruthenium metal complex to physically block the drug from acting until light removes the cage.
Also covered reported alongside — the timeline has no entry for these yet
-
first by Mirage News, 9d ago · also The National Tribune, Google News · Health
2 more headlines
- Researchers create light-activated cages for 'protein killer' molecules Phys.org · 9d ago
- Light-activated molecular cages offer precise control over protein degradation - News-Medical Google News · Health · 8d ago